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This open, clinical study describes the use of lamotrigine in 200 adults and children with drug resistant epilepsy. 
Lamotrigine was used largely as add-on therapy and outcome was assessed by the patients, parents and carers and 
the physician in terms of reduction of seizure frequency, drug side-effects and improvement inquality of life. Of 
the 200 patients, 70 (35%) were rendered seizure free. Lamotrigine was especially helpful in resistant primary 
generalized epilepsy, complex partial seizures, mixed seizures subsequent to brain damage, Lennox-Gastaut 
syndrome and in complex partial seizures which secondarily generalized. Fifty-three patients ceased lamotrigine; 30 
due to lack of effect, and 13 due to side-effects. Lamotrigine is a very useful antiepileptic medication of a ‘broad 
spectrum’ nature being effective in primary generalized epilepsy and partial seizures as add-on therapy. The 
side-effect profile is good with most side-effects being avoidable. 
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Introduction 
Initial experience with lamotrigine (LTG) has 
confirmed its anticonvulsant effect14. In the more 
recent past, it has become apparent that LTG is 
useful in primary generalized epilepsf-’ the 
Lennox-Gastaut Syndromes-” and in childhood 
epilepsyg~11-13. The present report describes the 
use of lamotrigine in 200 patients, adults and 
children with epilepsy. It describes the use of 
LTG in a variety of seizure types paying 
particular attention to seizure control, drug 
side-effects, quality of life and the withdrawal of 
existing antiepileptic drugs (AEDs). It is an open, 
uncontrolled study documenting clinical 
experience. 
PATIENTS AND METHODS 
This report is based on observations from 200 
patients who had taken LTG for at least six 
months, either continuing with the drug or having 
ceased it due to side-effects or a lack of effect. A 
lack of effect was defined as an absence of 
improvement in seizure control over four to six 
months. 
Because of the known interaction between 
LTG and sodium valproate (VPA), with the latter 
inhibiting the metabolism of the former, increas- 
ing its half life and blood levelsi4,“, LTG was 
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introduced slowly. In the first 30 patients studied, 
LTG was commenced at a dose of 25 mg every 
other day, increasing the dose every two weeks. 
Due to the occurrence of a rash in a number of 
these patients, the introductory dosage schedule 
was thereafter slowed down. In subsequent 
patients commenced on the drug, a schedule 
slower than that recommended by the manufac- 
turers was employed, commencing with a dose of 
12.5 mg every third day in patients also taking 
sodium valproate. The dose was increased every 
two weeks to 12.5 mg every second day, 12.5 mg 
twice daily, 12.5 mg mane and 25 mg nocte, 25 mg 
twice daily, 25 mg mane and 60mg nocte, 
50 mg b.d., 50 mg mane and 100 mg nocte, 100 mg 
twice daily and so on. 
Seizure control was assessed against baseline 
seizure frequency for the preceding three to six 
months. Of particular interest was a group of 67 
patients with cerebral palsy, or who had head 
injuries leading to epilepsy. This group, a real 
clinical entity, have been loosely called ‘patients 
with generalized seizures secondary to brain 
damage’. Seizure control was assessed as: 
Seizure eradication-no seizures for over six 
months. 
90% seizure reduction-very sporadic seizures in 
patients who were previously having numerous 
(at least daily) seizures. 
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~75% seizure reduction. 
~50% seizure reduction. 
~50% seizure reduction. 
No effect. 
Deterioration in seizure control. 
The patients have been followed up regularly, 
every one to three months, being asked about 
drug side-effects at all consultations. In particular, 
the frequency of rash was sought and signs of 
carbamazepine (CBZ) intoxication (diplopia, 
dizziness and ataxia) due to an interaction with 
LTG. Improvements in quality of life were 
assessed by patient, parent or carer report and 
physician observation. Whilst this may appear a 
bit ‘soft’, the changes in quality of life which 
occurred were very obvious. 
Antiepileptic drug blood level monitoring was 
carried out when clinically indicated and LTG 
levels were not measured as there is little 
relationship between blood level and seizure 
control. Pre-existing AEDs were withdrawn, on 
clinical grounds, where possible. 
RESULTS 
Two hundred patients were studied with the 147 
ongoing patients followed up for 1.75 f 0.8 
(0.5-4.1 years) since commencing lamotrigine. 
The patients were aged 21.8 f 13.1 (l-65) years 
of age and 109 were female. The duration of LTG 
therapy was 1.42 f 0.93 (0.01-4.1 years). 
A summary of the results is shown in Table 1. 
Overall, 70 patients (35%) were rendered seizure 
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free with the introduction of lamotrigine. This 
figure includes 13 patients with juvenile myoclinic 
epilepsy (JME) who were commenced on LTG 
due to unacceptable sodium valproate side-effects 
rather than poor seizure control. If the JME 
patients are excluded from the overall assessment 
of efficacy, 57 patients (30.8%) became seizure 
free. Sixty-two (31%) patients reported 83 
side-effects including 19 interactions with CBZ, 
six rashes, 17 episodes of therapeutic LTG 
intoxication, nine patients with insomnia, 26 
miscellaneous side-effects (headache, dizziness, 
agitation, tremor, etc.) and a deterioration in 
seizure control in six patients. Three patients, two 
with a rash and one who developed a stroke-like 
illness in association with LTG introduction, had 
the drug re-introduced commencing with 
12.5 mg/week, with good effect and no side- 
effects. Fifty-three patients ceased LTG, 30 due 
to a lack of effect, 13 due to side-effects, 4 due to 
both, 4 showed some effect but side-effects 
supervened, 1 patient had pseudo-epileptic seiz- 
ures and 1 patient took herself off all treatment. 
The 147 ongoing patients were taking 250 other 
AEDs of which, after introduction of LTG, 127 
AEDs were able to be withdrawn and 47 reduced 
(Table 2). The ongoing patients were taking 
5.6 f 2.8 (0.2-15) mg/kg/day of lamotrigine. 
Patients with generalized seizures secondary to 
brain damage 
Of 67 patients, 17 (25.4%) became seizure free, 
>90% seizure reduction in 16 patients (24%) 
Table 1: A summary of the results in the 200 patients being followed up 
Number of Ceased Seizure-free 
patients treatment patients 
Generalized 67 12 17 
secondary to brain 
damage 
CPS 24 11 8 
CPS with GTCS 38 16 8 
Primary generalized: 
JME 15 2 13 
Absences & GTCS 26 2 18 
Reading Epilepsy I 1 0 
Tonic 7 2 1 
Lennox-Gastaut 14 5 3 
SPS 4 2 1 
Landau-Kleffner 1 0 0 
ESES 1 0 0 
Angelman’s syndrome 1 0 1 
Batten’s disease 1 0 0 
200 53 70 
CPS, Complex partial seizure; GTCS, generalized tonic clonic seizure; JME, juvenile myoclonic 
epilepsy; SPS, simple partial seizures; ESES, epilepsy with electrical status epilepticus during slow sleep. 
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Table 2: Pre-existing AEDs successfully withdrawn or reduced following the addition of 
lamotrigine in the 147 ongoing patients 
AED Withdrawn Reduced 
Carbamazepine (CBZ) 
Sodium valproate (VPA) 
Clobazam (CLB) 
Vigabatrin (VGB) 
Clonazepam (CZP) 
Phenytoin (PHT) 
Nitrazepam (NZP) 
Ethosuximide (ESM) 
Diazepam (DZP) 
Felbamate (FBM) 
Phenobarbitone (PB) 
Acetazolamide (AZM) 
Prominal (PRM) 
Total 
44 
19 
19 
11 
11 
8 
3 
3 
2 
2 
127 
3 
35 
3 
2 
2 
0 
0 
0 
0 
0 
0 
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>75% in 11, >50% in ten and ~50% in one 
patient. Twelve patients ceased LTG treatment. 
In the 55 ongoing patients, there were nine 
episodes of LTG intoxication, two CBZ/LTG 
interactions, two instances of tremor, one of 
insomnia, one rash (successfully rechallenged) 
and a six-year-old patient taking VPA and NZP 
developed profound athetosis with LTG 
25 mg/day and total seizure control; this side- 
effect receded with a dose of 12.5 mg every third 
day producing >50% seizure control. 
Turning to quality of life, 45 of the 67 patients 
(67%) showed a marked improvement in 
alertness, cognition and quality of life. As many 
of these patients are severely disabled, this has to 
be seen in context. The improvements included 
increased awareness, a marked reduction in 
drooling, laughing, smiling, reaching out to 
people, responding much better to conversation 
and generally being a more active member of the 
family. Many of the patients slept less and several 
parents reported a change in sleep pattern with 
the patients remaining awake later in the 
evenings. 
Twelve patients ceased LTG, nine due to a lack 
of effect. One patient showed as increase in 
seizure frequency, another patient, despite a 
>50% improvement in seizure control, 
developed profound agitation and was pulling his 
hair out when taking VPA, CBZ and LTG 
2.5 mg/kg/day. Symptoms receded on 
withdrawing LTG. The final patient, a 25-year- 
old man taking VPA, CBZ and CLB, after taking 
4 doses of 25 mg LTG daily, developed a 
stroke-like illness which lasted three days, 
unassociated with any seizures. Lamotrigine was 
ceased and the symptoms resolved totally. A 
cerebral CT scan was normal. LTG has been 
successfully re-introduced in this patient. 
Complex partial seizures 
Of the 62 patients, 38 exhibited secondary 
generalization. Sixteen patients (26%) became 
seizure free, nine showed a ~90% improvement 
in seizure control, eight >75%, one >50%, one 
~50% and 25 patients ceased lamotrigine. One 
patient who was seizure free, but drug intoxicated 
with PHT and CZP, had lamotrigine introduced 
and CZP withdrawn. She is now alert and back at 
part-time studies, but has occasional complex 
partial seizures. In the 35 ongoing patients, there 
were five episodes of CBZ/LTG intoxication, 
resolved by lowering the CBZ dose and three 
patients developed LTG intoxication due to 
excessive dosage. Eleven patients (19%) showed 
a marked improvement in alertness and 
behaviour. 
Twenty-seven patients ceased LTG, 16 due to a 
lack of effect, one due to CBZ intoxication, three 
developed a rash, four showed increased seizure 
frequency, one developed severe headaches, one 
patient became dizzy and agitated and one 
patient decided she did not have epilepsy and 
ceased all her medications with unfortunate 
effect. All symptoms resolved with LTG with- 
drawal, except one patient with a vesicular rash 
which was not felt to be LTG related. 
Primary generalized epilepsy 
Juvenile myoclonic epilepsy 
There were 15 patients all of whom were free of 
major seizures, including the two patients not on 
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lamotrigine. Eleven of these 13 LTG patients 
have no GTCS and no myoclonus, whilst two 
have no GTCS but some morning myoclonus 
when sleep deprived. Two patients developed 
transient side-effects; lip and tongue swelling and 
in another patient, LTG intoxication. One patient 
ceased lamotrigine due to insomnia and being on 
a perpetual ‘high’ and the other patient, who 
takes CBZ, CLB and sulthiame, developed 
headaches with LTG and abandoned it. As 
previously mentioned, these patients were com- 
menced on LTG largely because of VPA side- 
effects:- weight gain, hair loss and fluid retention. 
Sodium valproate has so far been successfully 
withdrawn in four patients, of whom three have 
lost 7 of 11 kg weight gain, 5 of 22 kg and 4 of 7 kg 
weight gain. In the latter patient, hair loss has also 
ceased. In one other patient, violent dreams 
associated with VPA have ceased. 
Absences f generalized tonic- clonic seizures 
(GTCS) 
Of the 26 patients, 18 became seizure free, 1 
showed a >90% seizure reduction, three >75%, 
one ~50% and in the final patient GTCS are 
controlled and absences ~75% so. In terms of 
side-effects, one patient was therapeutically LTG 
intoxicated three times and one patient over- 
dosed herself. One patient already on VPA did 
not respond to LTG; telemetry showed the 
episodes to be non-epileptic. Finally, one patient 
ceased LTG due to double vision, headache and 
dizziness whilst also taking VPA. 
Tonic seizures (documented by video-EEG 
monitoring) 
Of the seven patients, one is seizure free, three 
have >90%, and one patient has a >50% 
reduction in seizures. Two patients have ceased 
LTG treatment. In the five ongoing patients, one 
patient had a CBZ/LTG interaction, one de- 
veloped LTG intoxication and all the patients 
have shown a marked improvement in quality of 
life. Two patients ceased LTG due to a lack of 
effect with one of these patients developing CBZ 
intoxication. 
Lennox-Gastaut syndrome 
There were 14 patients of whom three (21%) are 
now seizure free, two have shown a >90% 
reduction in seizures, one >75%, >50% in two 
patients, <50% in another patient and four have 
ceased treatment with LTG. In the ongoing nine 
patients, there were two episodes of CBZ 
intoxication, one of LTG intoxication and one 
patient had a rash .(successfully rechallenged). 
Seven of the nine patients have shown a marked 
improvement in alertness, motor skills and 
conversation. Five patients have ceased LTG 
treatment, four due to a lack of effect and one, 
lack of effect with marked drowsiness. 
Lamotrigine has been used in nine more 
patients. Four had simple partial seizures (SPS). 
A six-year-old girl with SPS, previously taking 
CBZ and CBL, is now off both drugs and seizure 
free on LTG 15 mg/kg/day. A nine-year-old girl 
has shown a >90% reduction in seizures with the 
addition of LTG to CBZ. Two other patients with 
SPS did not respond to lamotrigine and it has 
been withdrawn. Five other patients with a 
variety of forms of epilepsy have been tried on 
lamotrigine. The first is a 47-year-old man with 
reading epilepsy of 10 years duration taking VPA 
and CZP. When taking 6.2 mg/kg/day LTG there 
was a 90% reduction in seizures and taking 
6.2 mg/kg/day LTG there was a 90% reduction in 
seizures and CZP was withdrawn. He subse- 
quently developed an ‘autoimmune meningo- 
encephalitis’ and lest it be drug related, LTG was 
withdrawn, with a deterioration in seizure con- 
trol. An eight-year-old boy with ESES has shown 
behavioural improvement, but no EEG ame- 
lioration, with LTG 13 mg/kg/day. In the case of 
a five-year-old boy with Landau-Kleffner syn- 
drome, his absences have almost ceased and his 
speech and behaviour are much improved with 
LTG 2.5 mg/kg/day. A seven-year-old girl with 
Angelman’s Syndrome is now seizure free and 
much more alert taking VPA plus LTG 
5 mg/kg/day. Finally, a six-year-old girl with 
Batten’s Disease showed an initial good response 
to LTG (2 mg/kg/day) in addition to VPA and 
CZP. This has been lost as her disease has 
progressed. 
DISCUSSION 
Lamotrigine has been shown to be effective in 
both partial16-19 and generalized seizures20-u. The 
present report looks at the use of LTG as add-on 
therapy in clinical practice in a substantial 
number of patients presenting with treatment 
resistant seizures (excluding the JME patients). 
It showed that 30.8% became seizure free with 
the addition of lamotrigine. This was especially 
the case in those with absences f tonic-clonic 
seizures (69%), CPS (33%), brain damage with 
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resultant generalized seizures (25%), Lennox- 
Gastaut syndrome (21%) and a similar figure for 
CPS with secondary generalization. 
This data supports the existing evidence that 
LTG is of value in treatment resistant primary 
generalized epilepsy including juvenile myoclonic 
epilep#*=. In this present study where LTG 
was used in JME because of VPA side-effects, it 
has been possible to withdraw VPA in four 
patients and reduce the dose in all the others. The 
original side-effects have either been abolished or 
minimized. 
Lamotrigine was helpful in two other groups of 
patients where treatment is often unsatisfactory; 
Lennox-Gastaut syndrome and those with brain 
damage and resultant generalized, often mixed, 
seizures. Three patients (21%) with LGS became 
seizure free with 9/14 patients showing benefit in 
terms of seizure control and quality of life. These 
observations confirm growing evidence of the 
usefulness of lamotrigine in LGS’0”c28. The 
other group of patients with encouraging results 
was that composed of individuals with brain 
damage and mixed seizures. Some of these 
patient’s have been described in detail 
elsewhere29 and thus will be discussed only 
briefly. With the addition of lamotrigine, 25% 
became seizure free and a further 40% exhibited 
a >75%->90% reduction in seizures. As impor- 
tantly for the patient and their family, 67% 
showed an improvement in quality of life. 
When an additional AED is introduced with an 
improvement in seizure control, it is usual to try 
and withdraw some of the pre-existing medica- 
tions. In the present study it was possible to 
withdraw 51% of the previous AEDs in the 147 
ongoing patients especially CBZ, CLB, VGB and 
CZP. Sodium valproate could frequently be 
reduced in dosage, but withdrawal was more 
difficult and not infrequently associated with 
seizure recurrence. This suggests the possibility of 
synergism between these two AEDs as discussed 
elsewhere22*u. 
One of the important benefits of open studies is 
the accurate definition of side-effects as ex- 
perienced in clinical practice as opposed to 
clinical trials. Side-effects with LTG can be 
divided into four groups, three of which are 
avoidable. Firstly, the interaction with CBZ 
occurred in 9.5% of patients. This can be 
minimized by mentioning the interaction to the 
patient and instructing them to report at once if 
they develop diplopia, ataxia or dizziness and 
then cease the CBZ for 24 hours and subse- 
quently reduce the dosage by 25%. The sympt- 
oms recede in 48 hours. The second 
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problem is that of a rash which occurred in 3% of 
patients, all of whom were taking VPA. These 
patients were amongst the first 30 patients studied 
and since using the present slow rate of LTG 
introduction no further rashes have been seen. 
Thirdly, there were 17 episodes of LTG intoxica- 
tion due to excessive dosage increases. These 
three groups of side-effects should be largely 
avoidable. Of the remaining miscellaneous side- 
effects, the most important were an increase in 
seizure frequency (3%) and insomnia (4.5%). 
Finally, with all AEDs there is a concern about 
the development of tolerance. This is especially 
the case with the benzodiazepines, e.g. clobazam 
with tolerance rates varying from 9-19%302’, but 
also for VGB with figures ranging from 3%32 to 
10%33. In the present group of 147 ongoing 
patients there has to date been no suggestion of 
tolerance. This will need to be looked for over a 
more protracted period. 
The present report supports the growing view 
that LTG is a useful ‘broad spectrum’ AED with 
a good side-effect profile. 
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